Alterome Therapeutics has dosed the first patient in a Phase 1/1b trial of ALTA3263, a novel oral pan-KRAS inhibitor designed to target over 90% of KRAS mutations in advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.